Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Weekly Low-Dose Carboplatin and Paclitaxel in the Treatment of Recurrent Ovarian and Peritoneal Cancer

By Havrilesky L.J.   Alvarez A.A.   Sayer R.A.   Lancaster J.M.   Soper J.T.   Berchuck A.   Clarke-Pearson D.L.   Rodriguez G.C.   Carney M.E.  

Gynecologic Oncology, Vol. 88, Iss. 1, 2003-01 ,pp. : 51-57

Academic Press

Access to resources Recommend Favorite

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

By Tung N.   Berkowitz R.   Matulonis U.   Quartulli M.   Seiden M.   Kim Y.   Niloff J.   Cannistra S.A.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite

A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer

By Mori Taisuke   Hosokawa Kenichi   Kinoshita Yoshiyuki   Watanabe Ai   Yamaguchi Takeshi   Kuroboshi Haruo   Kato Yoshiko   Yasuda Jinsuke   Fujita Hiroyuki   Nakata Yoshinori   Honjo Hideo  

International Journal of Clinical Oncology, Vol. 12, Iss. 3, 2007-06 ,pp. : 205-211

Springer Publishing Company

Access to resources Recommend Favorite

Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors

By Matsuo Koji   Im Dwight   Rosenshein Neil  

International Journal of Clinical Oncology, Vol. 15, Iss. 3, 2010-06 ,pp. : 325-327

Springer Publishing Company

Access to resources Recommend Favorite